rs7530511 — IL23R Leu310Pro

IL23R Leu310Pro — The Rare Leucine Allele in Thyroid and Joint Autoimmunity

The interleukin-23 receptor (IL-23R¹¹ IL-23R
A transmembrane receptor subunit that pairs with IL-12Rβ1 to form the functional IL-23 receptor complex on Th17 cells, NK cells, and innate lymphoid cells) sits at a pivotal junction in the immune system: it receives signals from IL-23, a cytokine produced by dendritic cells and macrophages, and translates them into activation of Th17 cells²² Th17 cells
A subset of CD4+ helper T cells characterized by IL-17 production; central to mucosal immunity and implicated in many autoimmune diseases. rs7530511 introduces a missense change at codon 310 of IL-23R: the common C allele encodes Proline (Pro310), while the rare T allele encodes Leucine (Leu310). Globally, about 87% of people carry the C allele (Pro310) and only 13% carry the T allele, making the Leu310 form the minor variant. The TT homozygous (Leu/Leu) genotype is found in fewer than 2% of people of European descent and is extremely rare in East Asian populations (~0.02%).

The Mechanism

Position 310 of IL-23R falls within the fibronectin type III extracellular domain, a region involved in cytokine binding and receptor dimerization. Leucine and proline differ substantially in structure³³ Leucine and proline differ substantially in structure
Proline's cyclic pyrrolidine ring creates a rigid kink in the polypeptide chain, whereas leucine is a flexible branched-chain residue — substituting leucine for proline at a structurally constrained position can alter local protein conformation. Proline is the population-common form (encoded by C allele, the major allele in all continental populations); the Leucine form (T allele) appears to confer modestly altered receptor function or stability. Computational predictions rate the C allele (Pro) as tolerated by SIFT and benign by PolyPhen, consistent with it being the evolutionarily maintained common form in humans. The T allele (Leu) has a SIFT score of 1 (tolerated) for the missense change at this position, suggesting a subtle rather than dramatic functional perturbation.

The mechanistic consequence may lie in altered IL-23 binding affinity or downstream JAK2/TYK2⁴⁴ JAK2/TYK2
Janus kinase family members that associate with the cytoplasmic tails of IL-23R and IL-12Rβ1; activated upon IL-23 binding to phosphorylate STAT3 and STAT4 signaling. Carriers of the T (Leu) allele may experience a subtly different IL-23 signaling set-point, shifting Th17 cell activation thresholds and contributing to an autoimmune-prone immune environment in certain tissues — including the thyroid gland.

The Evidence

The most striking finding comes from Huber et al. 2008⁵⁵ Huber et al. 2008
216 Graves' disease patients and 368 controls in a North American Caucasian cohort; studied four IL23R variants for association with Graves' disease and Graves' ophthalmopathy, which found that the TT genotype (Leu/Leu) was significantly associated with Graves' disease overall (2.5% in GD patients vs. 0.3% in controls, OR = 9.4, p = 0.02). Unlike the other IL23R variants in that study (rs2201841 and rs10889677), rs7530511 did not specifically track with Graves' ophthalmopathy but with GD broadly — suggesting the Leu310 form shifts susceptibility to thyroid autoimmunity through a mechanism distinct from eye-tissue-specific inflammation.

In rheumatoid arthritis, Dogru et al. 2022⁶⁶ Dogru et al. 2022
Turkish cohort from the South Aegean region studying IL-23R polymorphisms in RA found the CT genotype significantly more common in RA patients than controls. When combined with the AA genotype of the nearby rs1004819, the combination reached OR 4.9 (p = 0.0001), underscoring how IL23R haplotype context amplifies risk.

The variant also appears in ulcerative colitis data: Lv et al. 2012⁷⁷ Lv et al. 2012
Chinese Han population cohort for ulcerative colitis found the variant allele more frequent in UC cases (3.3%) than controls (0.7%, p = 0.002), though the study population and small absolute difference suggest caution in generalization.

An important observation concerns the direction reversal across traits. A meta-analysis of 13 studies on IL23R and psoriasis⁸⁸ meta-analysis of 13 studies on IL23R and psoriasis
Capon et al. 2012, Inflamm Res found the T allele was protective against psoriasis (OR = 0.820, 95% CI 0.764–0.879, p = 0.001), the opposite direction from Graves' disease. This context-dependence — risk for one autoimmune condition, protection against another — is consistent with IL-23R's role as a central hub whose signaling calibration affects different disease-specific Th17 programs differentially.

Crucially, the association with Graves' disease does not replicate in East Asian populations: Ban et al. 2009⁹⁹ Ban et al. 2009
464 Japanese AITD patients and 179 controls with four IL23R SNPs studied found rs7530511 was not associated with GD, Graves' ophthalmopathy, or Hashimoto's thyroiditis in the Japanese cohort. The authors attributed this to ethnic specificity — and indeed, the T allele is very rare (~1.3%) in East Asian populations, making statistical power limited there. The Graves' disease signal is most relevant for individuals of European ancestry.

Overall evidence level is moderate: the Graves' disease finding is striking (OR 9.4) but based on a single moderate-sized Caucasian cohort; the RA and UC associations require replication; the direction reversal for psoriasis adds complexity. No clinical guidelines currently include this variant.

Practical Actions

For TT homozygotes of European ancestry, the Graves' disease association warrants proactive thyroid monitoring. Since Graves' disease is caused by stimulatory TSH-receptor antibodies driving thyroid overactivity, the key is early detection through TSH testing and TRAb (thyrotropin receptor antibody) measurement. Catching the disease before overt hyperthyroidism develops allows for less intensive treatment and better outcomes. CT heterozygotes carry an intermediate signal that warrants awareness but not aggressive screening absent symptoms.

Note that there is no supplement, diet, or lifestyle intervention known to counteract IL-23R-driven thyroid autoimmunity specifically. Selenium supplementation has independent evidence in autoimmune thyroiditis generally, but its benefit in rs7530511-specific Graves' disease susceptibility has not been studied.

Interactions

rs7530511 is one of several IL23R variants in the GeneOps database, each with distinct associations. rs11209026 (R381Q) is the most protective IL23R variant, strongly reducing IBD risk. rs2201841 (intronic) is associated with psoriasis and Crohn's susceptibility. rs1004819 appears to synergize with rs7530511 in rheumatoid arthritis (combined OR ≈ 4.9 when both risk genotypes are present). Individuals carrying risk genotypes at multiple IL23R loci may have a more broadly dysregulated IL-23/Th17 axis than any single variant predicts.

Beyond IL23R itself, interactions with other autoimmune loci — PTPN22 rs2476601 (R620W, a master autoimmunity risk variant affecting T-cell activation thresholds) and HLA-DR variants strongly associated with Graves' disease — are biologically expected but have not been quantified in combination with rs7530511 specifically.